CReATe > Home

Our Mission

The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium will enroll patients with sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The goals of the CReATe consortium are to advance therapeutic development for this group of neurodegenerative disorders through study of the relationship between clinical phenotype and underlying genotype, and also through the discovery and development of biomarkers.

CReATe Issues 2020 Pilot Project Request for Applications

The CReATe Consortium in partnership with the ALS Association has released a Biomarker Pilot Project Request for Applications (RFA). The submission deadline for Letters of Intent is January 17, 2020. Click here for details

CReATe Twitter

Tweets by @CReATeRDCRN

CReATe Podcasts

The CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.

Listen to "CReATe Podcast" on Spreaker.

All podcasts

CReATe Biorepository

Given the increasing recognition that the development and validation of biomarkers will require collaboration, the CReATe Consortium has established a repository of biological samples collected from patients.

Learn more

CReATe Research Studies

8001: Phenotype, Genotype & Biomarkers in ALS and Related Disorders
8002: Clinical Procedures To Support Research (CAPTURE)
8005: Limited Phenotype DNA Sequencing (LPSeq)
8007: Study of ALS Reversals 2: Genetic Analyses (St.A.R. Protocol 2)
8008: Biomarkers of axonal degeneration in Hereditary Spastic Paraplegia
8009: TRIAL READY

Join CReATe Connect! An RDCRN Contact Registry

CReATe Twitter

CReATe Podcasts

CReATe Biorepository

CReATe Research Studies

Join CReATe Connect!
An RDCRN Contact Registry